CRBU Projected Dividend Yield

Caribou Biosciences Inc ( NASDAQ : CRBU )

Caribou Biosciences is a clinical-stage Clustered Regularly Interspaced Short Palindromic Repeats genome-editing biopharmaceutical company focused on developing therapies for patients with devastating diseases. Co.'s CB-010 is a clinical-stage allogeneic anti-CD19 chimeric antigen receptor (CAR)-T (CAR-T) cell therapy with programmed cell death protein 1 removed from the CAR-T cell surface by a genome-edited knockout of the PDCDI gene. Co.'s CB-011 is an allogeneic CAR-T cell therapy that is an anti-B cell maturation antigen CAR-T cell therapy incorporating an immune cloaking approach. Co.'s CB-012 is an allogeneic CAR-T cell therapy targeting C-type lectin-like molecule-1.

20 YEAR PERFORMANCE RESULTS